We are live on ! Find out more
OMGA

Omega Therapeutics, Inc. Common Stock
OMGA

Delisted

OMGA was delisted on the 24th of February, 2025.

Back to rankings

1 hedge funds and large institutions have $0 invested in Omega Therapeutics, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% less funds holding

Funds holding: 4 → 1 (-3)

100% less capital invested

Capital invested by funds: $2.5K → $0 (-$2.5K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
1
Holders Change
-3
Holders Change %
-75%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$1.08K
2
PS
Principal Securities
Iowa
-$1.02K
3
SPIA
Steward Partners Investment Advisory
New York
-$405
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
1
Barclays
United Kingdom
– -$1.08K -13,278 Closed
SPIA
2
Steward Partners Investment Advisory
New York
– -$405 -5,000 Closed
PS
3
Principal Securities
Iowa
– -$1.02K -1,370 Closed

OMGA Hedge Fund Activity: Q2 2025 in Review

1 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q2 2025, worth a combined $0 — down 100% from $2.5K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of OMGA and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Barclays, exiting entirely with an estimated $1.08K sold.

  • 1 institutional investor held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q2 2025, down from 4 in Q1 2025.
  • Funds reported $0 of Omega Therapeutics, Inc. Common Stock stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q2 2025 and 3 closed out, a net change of -3 holders.
  • The largest Omega Therapeutics, Inc. Common Stock seller in Q2 2025 was Barclays, an estimated $1.08K sold.

Based on aggregated 13F filings for Q2 2025.